In particular the fraction of cancer cells in blood—that will be referred to as tumor burden from now on—can be reliably estimated by analyzing the expression level of the fusion gene BCR-ABL, thus providing an easy way to monitor the disease progression, as well the response to therapy. This evidence concerns the gene BCR and cancer.